PAM
ITCI

Paradigm Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Paradigm Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,000
Closed -$55.6K – 834
2016
Q1 		$55.6K Hold
2,000
– – 0.01% 563
2015
Q4 		$108K Buy
+2,000
New +$101K 0.02% 467

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Paradigm Asset Management's ITCI Position: Q2 2016 in Review

Paradigm Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2016, closing a stake of 2,000 shares — an estimated $55.6K sold.

Paradigm Asset Management first reported a position in ITCI in Q4 2015 and held it in 2 quarters. The position peaked at $108K in Q4 2015. 139 funds tracked by Wall St. Rank hold ITCI as of Q2 2016.

  • Paradigm Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2016 after selling out during the quarter.
  • Paradigm Asset Management sold 2,000 Intra-Cellular Therapies Inc. shares in Q2 2016, an estimated $55.6K.
  • Paradigm Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 2 quarters.
  • Paradigm Asset Management's Intra-Cellular Therapies Inc. position peaked at $108K in Q4 2015.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2016.

Based on Paradigm Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.